New RAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma

被引：24

作者：

Carlino, Matteo S. ^{[1
,2
,3
]}

Kwan, Vu ^{[3
]}

Miller, David K. ^{[4
,5
]}

Saunders, Catherine A. B. ^{[3
]}

Yip, Desmond ^{[6
,7
]}

Nagrial, Adnan M. ^{[8
]}

Tomlinson, Jeanne ^{[3
]}

Grimmond, Sean M. ^{[4
,5
]}

Scolyer, Richard A. ^{[9
,10
]}

Kefford, Richard F. ^{[1
,2
,3
,9
]}

Biankin, Andrew V. ^{[8
,11
,12
,13
]}

Long, Georgina V. ^{[9
,14
,15
]}

机构：

[1] Univ Sydney Westmead, Westmead Inst Canc Res, Sydney, NSW, Australia

[2] Millennium Inst, Sydney, NSW, Australia

[3] Westmead Hosp, Sydney, NSW, Australia

[4] Queensland Ctr Med Genom, Brisbane, Qld, Australia

[5] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia

[6] Canberra Hosp, Canberra, ACT, Australia

[7] Australian Natl Univ, Sch Med, Canberra, ACT, Australia

[8] Kinghorn Canc Ctr, Garvan Inst Med Res, Sydney, NSW, Australia

[9] Melanoma Inst Australia, Sydney, NSW, Australia

[10] Royal Prince Alfred Hosp, Sydney, NSW, Australia

[11] Univ New S Wales, South Western Sydney Clin Sch, Liverpool, Merseyside, England

[12] Univ Glasgow, Inst Canc Sci, Wolfson Wohl Canc Res Ctr, Glasgow, Lanark, Scotland

[13] Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland

[14] Univ Sydney, Sydney, NSW 2006, Australia

[15] Westmead Inst Canc Res, Sydney, NSW, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 11期

基金：

英国惠康基金;

关键词：

IMPROVED SURVIVAL; PROGRESSION; VEMURAFENIB; MUTATIONS;

D O I：

10.1200/JCO.2013.51.5783

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E52 / E56

页数：5

共 50 条

[1] COMBINED BRAF AND MEK INHIBITION IMPROVES OUTCOME IN METASTATIC MELANOMA
不详
CANCER DISCOVERY, 2012, 2 (11) : 971 - 971
[2] Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
Queirolo, Paola
Picasso, Virginia
Spagnolo, Francesco
CANCER TREATMENT REVIEWS, 2015, 41 (06) : 519 - 526
[3] Inhibition of BRAF and MEK in BRAF-mutant melanoma
Smalley, Keiran S. M.
Sondak, Vernon K.
LANCET, 2015, 386 (9992): : 410 - 412
[4] BRAF INHIBITION CAN INDUCE NONCUTANEOUS RAS-MUTANT CANCERS
不详
CANCER DISCOVERY, 2013, 3 (01) : 9 - 9
[5] BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
Richman, Juliet
Martin-Liberal, Juan
Diem, Stefan
Larkin, James
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (09) : 1285 - 1297
[6] Combined inhibition of BRAF and MEK in melanoma patients
Infante, Jeffrey R.
Swanton, Charles
LANCET ONCOLOGY, 2014, 15 (09): : 908 - 910
[7] Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V.
Stroyakovskiy, D.
Gogas, H.
Levchenko, E.
de Braud, F.
Larkin, J.
Garbe, C.
Jouary, T.
Hauschild, A.
Grob, J. J.
Sileni, V. Chiarion
Lebbe, C.
Mandala, M.
Millward, M.
Arance, A.
Bondarenko, I.
Haanen, J. B. A. G.
Hansson, J.
Utikal, J.
Ferraresi, V.
Kovalenko, N.
Mohr, P.
Probachai, V.
Schadendorf, D.
Nathan, P.
Robert, C.
Ribas, A.
DeMarini, D. J.
Irani, J. G.
Casey, M.
Ouellet, D.
Martin, A. -M.
Le, N.
Patel, K.
Flaherty, K.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (20): : 1877 - 1888
[8] Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition
Morales, Delphine
Vigneron, Pascale
Ferreira, Ines
Hamitou, Warda
Magnano, Mikael
Mahenthiran, Laxsika
Lok, Catherine
Vayssade, Muriel
CANCERS, 2021, 13 (19)
[9] Combined BRAF and MEK inhibition in BRAF-mutant NSCLC
Rivalland, Gareth
Mitchell, Paul
LANCET ONCOLOGY, 2016, 17 (07): : 860 - 862
[10] Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas
Donald Lawrence
Victoria Atkinson
Sachin Agarwal
Wilson H. Miller
Matteo S. Carlino
Rosalie Fisher
Georgina V. Long
F. Stephen Hodi
Jennifer Tsoi
Catherine S. Grasso
Bijoyesh Mookerjee
Qing Zhao
Razi Ghori
Blanca Homet Moreno
Nageatte Ibrahim
Omid Hamid
Nature Medicine, 2019, 25 : 936 - 940

← 1 2 3 4 5 →